pI: 8.3204 |
Length (AA): 275 |
MW (Da): 31461 |
Paralog Number:
1
Signal peptide: N | GPI Anchor: N | Predicted trans-membrane segments: 6
Targets have been classified into druggability groups (DG) according to their druggability score in network driven prioritizations. DGs range from 1 to 5; the higher the group number, the higher the chance of the target to be druggable
Modbase 3D models:
PDB Structures:
Ortholog group members (OG5_134360)
Species | Accession | Gene Product |
---|---|---|
Homo sapiens | ENSG00000164023 | sphingomyelin synthase 2 |
Mus musculus | ENSMUSG00000050931 | sphingomyelin synthase 2 |
Trypanosoma brucei gambiense | Tbg972.9.5360 | phosphatidylcholine:ceramide cholinephosphotransferase 2, putative |
Trypanosoma brucei gambiense | Tbg972.9.5370 | phosphatidylcholine:ceramide cholinephosphotransferase 2, putative |
Trypanosoma brucei gambiense | Tbg972.9.5320 | phosphatidylcholine:ceramide cholinephosphotransferase 2, putative |
Trypanosoma brucei | Tb927.9.9410 | inositol phosphorylceramide synthase |
Theileria parva | TP04_0631 | hypothetical protein |
Trichomonas vaginalis | TVAG_123040 | sphingomyelin synthetase, putative |
Trichomonas vaginalis | TVAG_032140 | sphingomyelin synthetase, putative |
Gene/Ortholog | Organism | Phenotype | Source Study |
---|---|---|---|
Tb09.211.1030 | Trypanosoma brucei | significant gain of fitness in bloodstream forms (3 days) | alsford |
Tb09.211.1030 | Trypanosoma brucei | significant gain of fitness in bloodstream forms (6 days) | alsford |
Tb09.211.1030 | Trypanosoma brucei | significant gain of fitness in procyclic forms | alsford |
Tb09.211.1030 | Trypanosoma brucei | no significant loss or gain of fitness in differentiation of procyclic to bloodstream forms | alsford |
alsford | High-throughput phenotyping using parallel sequencing of RNA interference targets in the African trypanosome | Genome Res 2011, 21:915-924 |
wormbase | C. elegans RNAi experiments | WormBase web site, http://www.wormbase.org, release WS170 |
keio | Systematic single-gene knock-out mutants of E. coli K12 | The Keio Collection |
shigen | Profiling of E. coli Chromosome (PEC) | National Institute of Genetics, Japan |
nmpdr | Genome-scale essentiality datasets from published studies (M. tuberculosis) | National Microbial Pathogen Data Resource |
yeastgenome | Systematic deletion of yeast genes | Saccharomyces Genome Database |
neb | C. elegans RNAi phenotypes | Data obtained from Wormbase WS150, curated by K. Chaudary and T. Carlow, New England Biolabs |
blattner | Systematic mutagenesis of the E. coli (MG1655) genome | J Bacteriol 2004, 186:4921-4930 |
gerdes | Experimental determination and system-level analysis of essential genes in E. coli MG1655 | Gerdes et al., J Bacteriol. 2003 185:5673-84 |
In TDR Targets, information about phenotypes that are caused by drugs, or by genetic manipulation of cells (e.g. gene knockouts or knockdowns) is manually curated from the literature. These descriptions help to describe the potential of the target for drug development. If no information is available for this gene or if the information is incomplete, this may mean that i) the papers containing this information either appeared after the curation effort for this organism was carried out or they were inadvertently missed by curators; or that ii) the curation effort for this organism has not yet started.
In any case, if you have information about papers containing relevant validation data for this target, please contact us.
Species | Known druggable target | Linked compounds | Reference |
---|---|---|---|
Homo sapiens | sphingomyelin synthase 2 | Compounds | References |